Paradromics CEO Matt Angle said the patient will start testing the device in the coming weeks with the goal of restoring her ability to communicate.

Neuralink rival Paradromics has implanted its Connexus brain chip in a woman who lost her speech to motor neuron disease, the first patient in its FDA study.

Paradromics CEO Matt Angle said the patient will start testing the device in the coming weeks with the goal of restoring her ability to communicate.